NPPA and Cognitive impairment: Alterations in the kynurenine pathway (KP) following CIS treatment suggest that certain KP metabolites may cross the blood–brain barrier, leading to increased production of the neuromodulator kynurenic acid (KYNA), which is associated with cognitive impairment.